Gilead CMO announces departure alongside two new exec appointments

pharmafile | August 15, 2018 | News story | Medical Communications, Research and Development Gilead, pharma 

Gilead has announced that its Chief Medical Officer is to vacate the role after just five months and leave the company in order to “pursue another opportunity”.

Dr Andrew Cheng will remain at Gilead until 7 September to aid in the transition period. The company also announced two new appointments alongside the news of Cheng’s departure: Dr Diana Brainard has been promoted from Vice President of Clinical Research to Senior Vice President of HIV and Emerging Viral Infections, while Gregg Alton, currently Executive Vice President of Corporate and Medical Affairs, will become the company’s first Chief Patient Officer.

“During his time at Gilead, Andrew played a definitive role in bringing forward new medicines that transformed the lives of millions of people with serious illnesses,” commented President and Chief Executive Officer Dr John Milligan, who also announced his departure from the company earlier this year. “Andrew played an especially critical part in advancing our portfolio of HIV products, and we’re extremely grateful for his many contributions and wish him all the best in the future. We are very pleased that Diana will lead this important therapeutic area for us going forward, as we seek to advance our next generation of HIV medicines, including potential options for prevention and perhaps one day a cure.”

“Gregg has a deep and broad understanding of the company and an unparalleled commitment to enabling access to our medicines for millions of people in both the developed and developing world,” he continued. “Bringing together into one organization a number of groups – including Access Operations & Emerging Markets, Public Affairs & Advocacy, Government Affairs, Medical Affairs, Digital Patient Solutions and the company’s commercial operations in certain countries in Asia – will help us better serve patients.”

Dr John McHutchison, Chief Scientific Officer and Head of Research and Development, also remarked: “Diana is an astute, knowledgeable and experienced clinician and researcher with broad expertise across the field of infectious diseases. She played an instrumental role in the rapid clinical development and approval of Gilead’s HCV medicines. The vision and leadership that she brings to this role will enable Gilead to continue to innovate, and advance new therapies for people with HIV and other emerging viruses.”

Matt Fellows

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …

Gilead acquires XinThera to strengthen pipeline in oncology and inflammation

Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech …


‘It’s Time for Trodelvy’: Charity launches petition against Gilead for drug access

The charity Breast Cancer Now has launched a petition calling on Gilead to provide free-of-charge …

Latest content